Live-attenuated CHIKV vaccine VLA1553 + Vaccine(s) approved for use during pregnancy by the MoH
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
18
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chikungunya Virus Infection
Conditions
Chikungunya Virus Infection
Trial Timeline
Mar 31, 2026 → Dec 31, 2027
NCT ID
NCT07414524About Live-attenuated CHIKV vaccine VLA1553 + Vaccine(s) approved for use during pregnancy by the MoH
Live-attenuated CHIKV vaccine VLA1553 + Vaccine(s) approved for use during pregnancy by the MoH is a pre-clinical stage product being developed by Valneva SE for Chikungunya Virus Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07414524. Target conditions include Chikungunya Virus Infection.
Hype Score Breakdown
Clinical
5
Activity
2
Company
5
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07414524 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Chikungunya Virus Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CHIKV VLP/unadjuvanted + CHIKV VLP/adjuvanted + Placebo | Bavarian Nordic | Phase 2 | 49 |
| Chikungunya | Bavarian Nordic | Phase 2 | 49 |
| CHIKV VLP vaccine booster + Placebo booster | Bavarian Nordic | Phase 3 | 74 |
| CHIKV VLP/adjuvant + Placebo | Bavarian Nordic | Phase 3 | 74 |
| CHIKV VLP, adjuvanted | Bavarian Nordic | Phase 2 | 49 |
| CHIKV VLP/adjuvant + Placebo | Bavarian Nordic | Phase 3 | 74 |
| CHIKV VLP vaccine + Placebo | Bavarian Nordic | Phase 3 | 74 |
| CHIKV VLP vaccine + Placebo | Bavarian Nordic | Phase 3 | 74 |
| Live-attenuated CHIKV vaccine VLA1553 | Valneva SE | Pre-clinical | 18 |
| VLA1553 | Valneva SE | Phase 3 | 72 |
| Live-attenuated CHIKV vaccine VLA1553 | Valneva SE | Pre-clinical | 18 |
| Biological Vaccine VLA1553 | Valneva SE | Phase 3 | 72 |
| VLA1553 full dose + VLA1553 half dose + Control | Valneva SE | Phase 2 | 47 |
| Active + Placebo | Valneva SE | Phase 3 | 72 |
| VLA1553 | Valneva SE | Phase 3 | 72 |
| VLA1553 + Control | Valneva SE | Phase 3 | 72 |
| VLA1553 + Placebo | Valneva SE | Phase 3 | 72 |
| VLA1553 | Valneva SE | Phase 1 | 28 |
| Live-attenuated CHIKV vaccine VLA1553 | Valneva SE | Pre-clinical | 18 |
| INTERCEPT Platelets | Cerus | Pre-clinical | 15 |